Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Reexamination Certificate
2001-06-11
2003-07-08
Huff, Sheela (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
Reexamination Certificate
active
06589988
ABSTRACT:
FIELD OF THE INVENTION
The invention concerns a pharmaceutical composition with antitumor activity based on carboplatin and comprising an aqueous solution of carboplatin with a carboplatin content of from 1 to 20 mg/ml.
PRIOR ART
Carboplatin (cis-diammin-1,1-cyclobutanedicarboxylatoplatinum(II) complex) is an active substance which is useful in treatment of tumors. This platinum cytostatic agent was introduced into medicinal practice in 1986 in a form of freeze dried powder for injection containing mannitol as a pharmaceutically acceptable trituration agent. Although the freeze dried product is stable, production of dry injections by freeze drying consumes much time and energy. The disadvantage in application of the lyophilization form of carboplatin is in cumbersome preparation of the carboplatin solution for infusion application; there exists, moreover, a certain risk for personnel based on possible interaction of carboplatin with DNA leading to chromosomal aberations. Namely these disadvantages motivated the efforts to prepare a liquid medicinal form of carboplatin which, due to limited manipulation, would lead to a decrease of risk of contamination of the environment and the medical personnel.
The basic problem in production of a liquid drug form of carboplatin is based on the fact that solutions of carboplatin in water or certain water solutions are stable and therapeutically useful only in a time interval of several hours or days. After this time, unwanted highly toxic aquacomplexes and/or other toxic substances are being formed in big extent in solutions of carboplatin. Solving the stability of carboplatin in aqueous solutions is therefore crucial for commercial application of aqueous solutions of carboplatin.
European patent document EP 334 551 describes a liquid drug form of carboplatin which is stabilized by addition of mannitol and benzyl alcohol which serve herein as conservation agents. The disadvantage of this way of stabilization is in that it does not solve the long-term stability of aqueous solutions of carboplatin. The European patent document EP 401896 describes an aqueous drug form of carboplatin which is stabilized by a buffer maintaining the pH value of the aqueous solution of carboplatin in the range of 2-6. In the patent document CZ 281349, there is described an aqueous drug form of carboplatin which is stabilized by presence of from 0.01 to 0.5 mg/ml of 1,1-cyclobutanedicarboxylic acid and/or its ammonium, sodium or potassium salt. The patent document EP 642 792 describes an aqueous drug form of carboplatin which is stabilized by presence of 0.25 to 4 mg/ml of 1,1-cyclobutanedicarboxylic acid or its alkaline metal salt maintaining the pH of the solution in the range of from 4 to 7. Finally, the patent document PCT WO95-20956 describes an aqueous drug form of carboplatin the stability of which is assured by the pH value of the carboplatin solution in the range of from 2.5 to 7 and by the presence of 1,1-cyclobutanedicarboxylic acid and/or its sodium, potassium or ammonium salt, whereby the obligatory part of this solution is that at least 1.10
−4
mg/ml of these compounds are present in a form of mono- or bivalent anion.
It is apparent from the hereinabove that there exists a conviction among persons skilled in this art that the presence of 1,1-cyclobutanedicarboxylic acid and/or its above cited salts is absolutely necessary for to attain certain acceptable stability of aqueous solutions of carboplatin.
After a thorough study of kinetics of carboplatin hydrolysis in aqueous solutions, this professional prejudice specified above has been now overcome by a new and surprising finding which may be summarized in a statement that the presence of a whatever acid facilitates the hydrolysis of carboplatin by an electrophilic attack of carboxylic ligands of carboplatin. Similarly, any nucleophilic compound which possesses stronger nucleophilicity than water may decrease the stability of carboplatin due to a substitution of the carboxylate ligand of carboplatin. Thus, any presence of a buffer including the 1,1-cyclobutanedicarboxylic acid and/or its conjugated base in a form of a salt will, contrary to expectations, decrease the stability of carboplatin in an aqueous solution. In variance with the so far accepted conviction, the most stable aqueous drug form of carboplatin is an aqueous solution of a highly pure carboplatin in a sterile water for injection, without any other components, namely nucleophilic compounds or acids.
DESCRIPTION OF THE INVENTION
An object of the present invention is thus a pharmaceutical composition with antitumor activity based on carboplatin and comprising an aqueous solution of carboplatin with the carboplatin content from 1 to 20 mg·ml
−1
, characterized in that it contains immediately after its preparation less than 0.1% by weight 1,1-cyclobutanedicarboxylic acid (“CBDCA”) and/or salt thereof, based on the weight of the present carboplatin.
Presumed mechanism of decomposition of carboplatin which is analogical to the disclosed mechanism of hydratation of cisplatin (Cheung Y. W., Cradock J. C., Vishnuvajjala B. B., Flora K. P., Am. J. Hosp. Pharm., 1987,44,124) is a two-step hydrolysis to mono- and diaquacomplexes of platinum of the formulas I and II:
The first step of decomposition of carboplatin in an aqueous solution according to the equation /1-0/ which causes the instability can be further generalised by the equation /1-1/:
It is apparent from the equations /1-0/ and /1-1/ that each acid or each nucleophilic compound which is a stronger nucleophile than water will decrease the stability of carboplatin by a mechanism of substitution of the carboxylate ligand of carboplatin. Although this presumption from the equation /1-1/ is logical, it is in the contrary to all the so far published statements. For to support the overcoming of the above formulated professional prejudice by evidences, there were collected and worked up data from stability studies of liquid carboplatin injections which differed in content of 1,1-cyclobutanecarboxylic acid and/or their salts.
The rate of hydrolysis of carboplatin to a monoaquacomplex of the formula (1) has been presumed to be of the first order in relation to carboplatin concentration and independent to water concentration:
r
CP
=
-
ⅆ
c
CP
ⅆ
t
=
k
O
·
c
H2O
·
c
CP
=
k
1
·
c
CP
-
ⅆ
c
CP
c
CP
=
k
1
·
ⅆ
t
,
which
may
be
integrated
to
:
/1-2/
ln
c
CP
c
CP0
=
-
k
1
·
t
,
which
may
be
laid
out
as
:
ln
(
1
-
x
)
=
-
k
1
·
t
/1-3/
Dependences on concentration according to equations /1-2/ and /1-3/ were evaluated by linear regression and the rate constant and/or the reaction rate of the carboplatin decomposition have been calculated.
Study of the decomposition rate of carboplatin in dependence on the concentration of 1,1-cyclobutanedicarboxylic acid.
Mean starting concentration of carboplatin was 10.0 mg·ml
−1
. Starting concentrations of 1,1-cyclobutanedicarboxylic acid were 0.017, 0.129, 1.189 and 14.804 mg·ml
−1
. The temperature and relative humidity during storage was 25° C./60% and 35° C./60%. The vials with samples were stored stopper upright.
The decrease of carboplatin content was calculated as a difference of carboplatin content between a reference and measured sample. The concentration data were evaluated according to equation /1-2/, whereby, due to a good linear relation, the data were evaluated by linear regression.
The calculated decomposition rates of carboplatin (r, /mol·m
−3
·s
−1
/) are summarised in the table:
concentration of 1,1-
cyclobutanedicarbo-
Storage temperature
xylic acid (mg · ml
−1
)
25° C.
35° C.
0.017
4.0 · 10
−9
4.9 · 10
−8
0.129
4.0 · 10
−9
5.1 · 10
−8
1.189
9.4 · 10
−9
7.3 · 10
−8
14.804
2.2 · 10
−8
Gust Ronald
Kysilka VladimíR
Male{haeck over (c)}ek Miroslav
Zatloukalová Libu{haeck over (s)}e
Huff Sheela
Notaro & Michalos P.C.
Pliva-Lachema A.S.
LandOfFree
Pharmaceutical composition with antitumor activity on the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition with antitumor activity on the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition with antitumor activity on the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3013675